Clinical trials: Metastatic Non-Squamous Non-Small Cell Lung Cancer
Squamous Non-small Cell Lung Cancer
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients
This is a multi-center, open-label Phase Ib dose escalation part followed by a randomized double-blinded placebo controlled Phase II part.
- Trial name
- NCT01911325
- Testing
- Buparlisib, Docetaxel
- Where
- 16 sites in United States, Belgium and 6 more
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or…
- Trial name
- NCT05277051
- Testing
- Remzistotug, Dostarlimab, Belrestotug
- Where
- 26 sites in United States, Australia and 7 more
- Volunteers
- 152 people
- Sponsor
- GlaxoSmithKline
Non-Small Cell Lung Cancer
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study was to see how well three investigational drugs worked together in preventing progression of the disease.
- Trial name
- NCT00356122
- Testing
- Docetaxel, Oxaliplatin, Bevacizumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Sanofi
Non-small Cell Lung Cancer, Head and Neck Cancer
A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
This is a Phase 1/2a, open-label, multi-center study of JAB-3068 in Patients with advanced solid tumors.This study has two phases: dose escalation phase and dose expansion phase.
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
- Trial name
- NCT03565003
- Testing
- JAB-3068
- Where
- 4 sites in China
- Volunteers
- 126 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.